secwatch.observer — SEC 8-K summary
======================================

Issuer:     ULTRALIFE CORP (ULBI)
CIK:        0000875657
Form:       8-K
Filed at:   2024-02-15T23:59:59+00:00
Accession:  0001437749-24-004266
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ultralife Q4 revenue $44.5M (+23.4% YoY); adjusted EPS $0.18 vs -$0.03
----------------------------------------------------------------------

- Q4 2023 sales $44.5M, up 23.4% YoY; full-year sales $158.6M, up 20.3%.
- Q4 operating income $3.6M vs $0.2M; full-year $9.5M vs $0.1M.
- Q4 adjusted EPS $0.18 vs loss of $0.03; full-year adjusted EPS $0.52 vs loss of $0.07.
- Medical battery sales highest quarter ever; Battery & Energy gross margin expanded 360 bps to 25.2%.
- Backlog $103.5M at year-end; management plans to pay down acquisition debt.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875657/000143774924004266/0001437749-24-004266-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875657/000143774924004266/ulbi20240214_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-004266

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer